You are here: Industry Insights > tanezumab

News List

FDA panel votes against Pfizer’s tanezumab for osteoarthritis pain pharmaceutical-technology
March 29, 2021
A joint FDA advisory committee has rejected a risk mitigation proposal for Pfizer and Eli Lilly’s osteoarthritis (OA) drug tanezumab, concluding that the drug’s safety risk to patients is too high.
FDA Accepts Regulatory Submission for Tanezumab americanpharmaceuticalreview
March 04, 2020
Pfizer and Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC) ...
Tanezumab Improves Scores for Pain, Function in Osteoarthritis drugs
July 04, 2019
Tanezumab Improves Scores for Pain, Function in Osteoarthritis.
Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial pharmaceutical-business-review
April 23, 2019
Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis worldpharmanews
April 23, 2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg.
More positive results for Pfizer/Lilly’s non-opioid pain drug pharmaphorum
February 22, 2019
Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).
Pfizer, Lilly Announce Top-line Results from Tanezumab Phase 3 Study americanpharmaceuticalreview
February 20, 2019
Pfizer and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP)....
Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain worldpharmanews
January 30, 2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.
Pfizer, Eli Lilly report detailed results from late-stage study of NGF inhibitor tanezumab in osteoarthritis pain firstwordpharma
October 25, 2018
Pfizer, Eli Lilly report detailed results from late-stage study of NGF inhibitor tanezumab in osteoarthritis pain
Ups and Downs! Pain Medication Tanezumab of Pfizer/Eli Lilly to See the Dawn amid Twists and Turns? Mr. Nanguo
August 01, 2018
Pfizer and Eli Lilly jointly announced recently that the Phase III trial of their anti-NGF antibody: tanezumab for the treatment of osteoarthritis (OA) pain met all the 3 endpoints.